Sociodemographic disparities in the use of GLP-1 receptor agonists and SGLT-2 inhibitors among US adults with type 2 diabetes: NHANES 2005-March 2020 medrxiv.org/content/10.1101/20

Sign in to participate in the conversation
CleverLibre Social

CleverLibre Social is an inclusive social instance for open discussion, learning, and community.
All cultures welcome.
Hate speech and harassment strictly forbidden.